«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2022 02

Page:

221-225

Research Field:

Publishing date:

Info

Title:

Analysis of influencing factors of cervical lymph node metastasis in thyroid papillary microcarcinoma

Author(s):

YIN Yirong¹; WANG Xiuxiu²; YU Xiaolong¹; ZHAO Wenjuan¹; SHEN Baoming³; LI Chengqian¹

1.Department of Endocrinology and Metabolism;3.Department of Information Management,the Affiliated Hospital of Qingdao University,Shandong Qingdao 266003,China;2.Department of Endocrinology,Qingdao Central Hospital,Shandong Qingdao 266011,China.

Keywords:

lymph node metastasis; papillary thyroid microcarcinoma; clinicopathological features

PACS:

R736.1

DOI:

10.3969/j.issn.1672-4992.2022.02.009

Abstract:

Objective：To investigate the influencing factors of lymph node metastasis (LNM) in papillary thyroid microcarcinoma (PTMC).Methods:Clinical data of 535 patients with thyroidectomy and pathologically confirmed PTMC were analyzed to compare the clinicopathological characteristics of PTMC patients with lymph node metastasis and non-lymph node metastasis,different metastatic regions,different tumor diameter,and further analyze the correlation between lymph node metastasis and PTMC clinicopathological characteristics.Results:There were 192 patients (35.89%) in the PTMC combined with lymph node metastasis group and 343 patients (64.11%) in the non-lymph node metastasis group.The proportion of age<55 years,male,multiple foci,bilateral distribution,>0.5 cm in diameter,Hashimoto's thyroiditis(HT),and medium/high-risk recurrence in lymph node metastasis group were significantly higher (all P＜0.05).There were 147 patients (76.56%) in the central lymph node metastasis (CLNM) group,and 45 cases (23.44%) in the lateral lymph node metastasis (LLNM) group.Compared with the CLNM group,the proportion of multiple foci,bilateral distribution,HT were higher,the proportion of BRAF mutation was lower in the LLNM group (all P＜0.05).There were 187 cases (34.95%) in the group of ≤0.5 cm in diameter and 348 cases (65.05%) in the group of >0.5 cm in diameter.Compared with the group of ≤0.5 cm,the proportion of multiple foci,bilateral distribution,lymph node metastasis,extra-capsular invasion,and medium/high risk recurrence were significantly higher in the group of >0.5 cm in diameter (all P＜0.05).Logistic regression analysis showed that age<55,male,multiple foci,>0.5 cm in diameter,and HT were risk factors of lymph node metastasis (all P＜0.05).Conclusion:Age<55 years,male,multiple foci,>0.5 cm in diameter,and HT were independent risk factors for PTMC lymph node metastasis,and lymph node metastasis increases the risk of PTMC recurrence.

References:

［1］SIEGEL RL,MILLER KD,JEMAL A.Cancer statistics,2016［J］.CA:A Cancer Journal for Clinicians,2016,66(1):7-30.
［2］郑克思,曾勇,陈聪，等.基于监测、流行病学和最终结果数据库甲状腺乳头状微癌颈部淋巴结转移的危险因素［J］.中国医学科学院学报,2018,40(06):736-743. ZHENG KS,ZENG Y,CHEN C,et al.Risk factors for cervical lymph node metastasis in thyroid papillary microcarcinoma based on surveillance,epidemiology,and database of final results［J］.Acta Academiae Medicinae Sinicae,2018,40(06):736-743.
［3］WANG K,XU J,LI S,et al.Population-based study evaluating and predicting the probability of death resulting from thyroid cancer among patients with papillary thyroid microcarcinoma［J］.Cancer Medicine,2019,8(16):6977-6985.
［4］XUE S,WANG P,HURST ZA,et al.Active surveillance for papillary thyroid microcarcinoma:Challenges and prospects［J］.Frontiers in Endocrinology,2018,9:736.
［5］程若川,杨婷婷.2016版中国甲状腺微小乳头状癌诊断与治疗专家共识解读［J］.中国实用内科杂志,2019,39(04):351-357. CHENG RC,YANG TT.2016 edition of Chinese diagnosis and treatment of thyroid micropapillary carcinoma expert consensus interpretation ［J］.Chinese Journal of Practical Internal Medicine,2019,39(04):351-357.
［6］中华人民共和国国家卫生健康委员会.甲状腺癌诊疗规范(2018年版)［J］.中华普通外科学文献（电子版）,2019,13(1):1-15. National Health Commission of the People's Republic of China.Guidelines for the diagnosis and treatment of thyroid cancer (2018 edition) ［J］.Chinese Archives of General Surgery (Electronic Edition),2019,13(1):1-15.
［7］HAUGEN BR,ALEXANDER EK,BIBLE KC,et al.2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer:The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer［J］.Thyroid,2016,26(1):1-133.
［8］KITAHARA CM,SOSA JA.The changing incidence of thyroid cancer［J］.Nature Reviews,2016,12(11):646-653.
［9］MCGUIRE S.World Cancer Report 2014.Geneva,Switzerland:World Health Organization,International Agency for Research on Cancer,WHO Press,2015［J］.Advances in Nutrition (Bethesda,Md.),2016,7(2):418-419.
［10］KIM KE,KIM EK,YOON JH,et al.Preoperative prediction of central lymph node metastasis in thyroid papillary microcarcinoma using clinicopathologic and sonographic features［J］.World Journal of Surgery,2013,37(2):385-391.
［11］KIM BY,JUNG CH,KIM JW,et al.Impact of clinicopathologic factors on subclinical central lymph node metastasis in papillary thyroid microcarcinoma［J］.Yonsei Medical Journal,2012,53(5):924-930.
［12］钱军,马云海,苏艳军，等.甲状腺乳头状癌中央区淋巴结清扫范围的合理选择［J］.中国肿瘤,2015,24(06):444-447. QIAN J,MA YH,SU YJ,et al.Rational selection of lymph node dissection in central area of thyroid papillary carcinoma［J］.China Cancer,2015,24(06):444-447.
［13］KIM TY,HONG SJ,KIM JM,et al.Prognostic parameters for recurrence of papillary thyroid microcarcinoma［J］.BMC Cancer,2008,8:296.
［14］LUO Y,ZHAO Y,CHEN K,et al.Clinical analysis of cervical lymph node metastasis risk factors in patients with papillary thyroid microcarcinoma［J］.J Endocrinol Invest,2019,42(2):227-236.
［15］BOELAERT K,HORACEK J,HOLDER RL,et al.Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration［J］.The Journal of Clinical Endocrinology and Metabolism,2006,91(11):4295-4301.
［16］朱敏,王护国,张英,等.甲状腺乳头状癌合并慢性淋巴细胞性甲状腺炎的临床病理特征分析［J］.中国普外基础与临床杂志,2018,25(03):307-311. ZHU M,WANG HG,ZHANG Y,et al.Analysis of the clinicopathological features of papillary thyroid carcinoma with chronic lymphocytic thyroiditis ［J］.Chinese Journal of Basic and Clinical Medicine,2018,25(03):307-311.
［17］郑荆洲,童传明,吴高松.微小甲状腺癌合并桥本氏甲状腺炎的临床病理及颈淋巴结转移特征［J］.中国普通外科杂志,2014,23(11):1557-1560. ZHENG JZ,TONG CM,WU GS.The clinicopathologic features and cervical lymph node metastasis of microthyroid carcinoma with hashimoto's thyroiditis［J］.Chinese Journal of General Surgery,2014,23(11):1557-1560.
［18］ZHANG L,YANG J,SUN Q,et al.Risk factors for lymph node metastasis in papillary thyroid microcarcinoma:Older patients with fewer lymph node metastases［J］.Eur J Surg Oncol,2016,42(10):1478-1482.
［19］FEI L,GUANGQI C,CHUNJUN S,et al.BRAFV600E mutation in papillary thyroid microcarcinoma:a meta-analysis ［J］.Endocrine-Related Cancer,2015,22(2):159-168.
［20］薛金才,刘勤江,田尤新,等.BRAF~(V600E)及TERT启动子突变在甲状腺微小乳头状癌风险评估中的价值［J］.中国癌症杂志,2018,28(05):335-341. XUE JC,LIU QJ,TIAN YX,et al.Value of BRAF~(V600E) and TERT promoter mutations in risk assessment of thyroid micropapillary carcinoma［J］.China Oncology,2018,28(05):335-341.
［21］KIM K,ZHENG X,KIM JK,et al.The contributing factors for lateral neck lymph node metastasis in papillary thyroid microcarcinoma (PTMC)［R/OL］.Endocrine,2020［2020-03-07］.https://doi.org/10.1007/s12020-020-02251-2.
［22］ZHENG X,PENG C,GAO M,et al.Risk factors for cervical lymph node metastasis in papillary thyroid microcarcinoma:a study of 1 587 patients［J］.Cancer Biology & Medicine,2019,16(1):121-130.
［23］HUANG XP,YE TT,ZHANG L,et al.Sonographic features of papillary thyroid microcarcinoma predicting high-volume central neck lymph node metastasis［J］.Surgical Oncology,2018,27(2):172-176.
［24］PISANU A,SABA A,PODDA M,et al.Nodal metastasis and recurrence in papillary thyroid microcarcinoma［J］.Endocrine,2015,48(2):575-581.
［25］WEN X,WANG B,JIN Q,et al.Thyroid antibody status is associated with central lymph node metastases in papillary thyroid carcinoma patients with Hashimoto's thyroiditis［J］.Ann Surg Oncol,2019,26(6):1751-1758.

Memo

Memo:

山东省自然科学基金(编号：ZR2016HM29)

Common functions

Last Update: 1900-01-01